Golden logoGolden logo
Advanced Search
Emergent BioSolutions

Emergent BioSolutions

A life sciences company with a focus on biotechnology and vaccines. It was founded in 1998 and is located in Gaithersburg, Maryland.

Emergent BioSolutions is a Maryland-based biotechnology company that develops and manufactures healthcare solutions. It manufactures products, platforms, and other technologies to address public health threats. Its therapies have been used in the past for illnesses such as anthrax and botulism.

COVID-19

In 2020, Emergent BioSolutions partnered with Vaxart, a biotechnology company, to aid with developing and manufacturing Vaxart’s experimental oral vaccine candidate for COVID-19. The company is expected to produce a bulk quantity of the vaccine so that Vaxart can initiate its pre-clinical studies.

Emergent BioSolutions also partnered with Novavax, Inc. to develop and manufacture a COVID-19 vaccine candidate. According to the press release announcing the collaboration, announced in mid-March 2020, "Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and utilizing their proprietary Matrix-M™ adjuvant to enhance immune responses. Emergent has initiated work for this program anticipating that the COVID-19 experimental vaccine candidate will be used in a Phase 1 clinical study within the next four months."

Emergent BioSolutions has partnered with the US government to expedite the development of a plasma-derived therapy, COVID-Human Immune Globulin (COVID-HIG) for severe hospitalized and high-risk patients to prevent progression to severe symptoms. The company received $14.5 million from BARDA in support of the program. COVID-HIG is a candidate human hyperimmune product, polyclonal antibody therapeutics, that will be manufactured using plasma donated from people who recovered from COVID-19 and have antibodies to SARS-CoV-2.

Timeline

April 3, 2020
Emergent BioSolutions raises a $14,500,000 grant from Biomedical Advanced Research and Development Authority.
September 25, 2019
Emergent BioSolutions raises a $20,000,000 grant.

Funding Rounds

Products

Patents

Further Resources

Title
Author
Link
Type
Date

Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease | Emergent BioSolutions Inc.

Emergent BioSolutions

Web

March 10, 2020

Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help

Adam Smith

Web

April 5, 2020

Emergent Biosolutions, Inc. (NYSE:EBS), Novavax, Inc. (NASDAQ:NVAX) - Emergent BioSolutions CEO Talks ...

Jayson Derrick

Web

March 12, 2020

Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus (Covid-19) Vaccine Candidate

BioSpace

Web

March 18, 2020

News

Title
Author
Date
Publisher
Description
The Associated Press
July 29, 2021
CTVNews
The U.S. Food and Drug Administration is allowing the problem-plagued factory of contract manufacturer Emergent BioSolutions to resume production of COVID-19 vaccine, the company said Thursday.
By LINDA A. JOHNSON
July 29, 2021
AP NEWS
The U.S. Food and Drug Administration is allowing the problem-plagued factory of contract manufacturer Emergent BioSolutions to resume production of COVID-19 vaccine bulk substance to resume, the company said Thursday.
Brandon May
July 7, 2021
BioSpace
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson's COVID-19 vaccine, Emergent is now facing a shareholder lawsuit accusing the company of insider trading.
Rosen Law Firm, P.A.
June 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between...
Kahn Swick & Foti, LLC
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms of Service.